x
MN 553 Pharmacology Exam 2 2024
x x x x x x
What xproperties xaffect xthe xdistribution xof xdrugs x- xdrug xsize, xcharge, xchemical xstructure,
xpH, x
x
molecular xsize, xlipid xor xwater
xsolubility
x
first xpass xmetabolism x- xmetabolism xby xthe xliver xfollowing xoral xadministration x
x
Phase x1 xreactions x- xOxidation, xreduction, xhydrolysis xor xnon-synthetic xreactions xthat
xprepare x
x
the xdrug xfor xfurther xmetabolism x- xto xmake xthe xdrug xmore xwater
xsoluble
x
Phase xII xreactions x- xsynthetic xor xconjugation xreactions, xsomething xis xadded xto xdrug xto
xmake xit x
x
more xwater xsoluble xand xmore xeasily xexcreted xby xthe
xkidneys
x
CYP xP450 x- xLiver x*enzyme* x that x detoxifies
xsubstances,
x
Makes xthem xeasier xto xbe
xexcreted.
x
single xnucleotide xpolymorphism x(SNP) x- xminor xmutations xthat xcan xresult xin xmetabolic
xactivity x
x
changes, xincluding xincreased xand xdecreased xdrug
xresponses
x
primary xorgan xof xexcretion xfor xdrugs x- xkidney x
x
blood xflow xdifferences xin xinfants x- xincreased xblood xflow xto xmuscles x1-6 xmo xEXCEPT
xduring x
x
illness, xcan xcause xslower xor xrapid
xperfusion
x
Pediatric xGI xfunction x- xpH xincreases xgradually- xreaches xadult xlevels x@ x20-30
xmonths x
x
preemies xare xeven
xslower
x
Diarrhea xand xkids x- xkids xwith xdiarrhea xhave xpoor xabsorption xof xoral xdrugs x
x
Pediatric xskin xabsorption x- xKids xhave xthinner xstratum xcorneum xso xtopical xmedications
xare x
x
absorbed xmore xreadily: xincreased xrisk xof
xtoxicity
x
Infants xand xLipid xSoluble xdrugs x- xdecreased xvolume xdistribution, xless xplasma xproteins
xfor x
MN 553 Pharmacology Exam 2 2024
x x x x x x
What xproperties xaffect xthe xdistribution xof xdrugs x- xdrug xsize, xcharge, xchemical xstructure,
xpH, x
x
molecular xsize, xlipid xor xwater
xsolubility
x
first xpass xmetabolism x- xmetabolism xby xthe xliver xfollowing xoral xadministration x
x
Phase x1 xreactions x- xOxidation, xreduction, xhydrolysis xor xnon-synthetic xreactions xthat
xprepare x
x
the xdrug xfor xfurther xmetabolism x- xto xmake xthe xdrug xmore xwater
xsoluble
x
Phase xII xreactions x- xsynthetic xor xconjugation xreactions, xsomething xis xadded xto xdrug xto
xmake xit x
x
more xwater xsoluble xand xmore xeasily xexcreted xby xthe
xkidneys
x
CYP xP450 x- xLiver x*enzyme* x that x detoxifies
xsubstances,
x
Makes xthem xeasier xto xbe
xexcreted.
x
single xnucleotide xpolymorphism x(SNP) x- xminor xmutations xthat xcan xresult xin xmetabolic
xactivity x
x
changes, xincluding xincreased xand xdecreased xdrug
xresponses
x
primary xorgan xof xexcretion xfor xdrugs x- xkidney x
x
blood xflow xdifferences xin xinfants x- xincreased xblood xflow xto xmuscles x1-6 xmo xEXCEPT
xduring x
x
illness, xcan xcause xslower xor xrapid
xperfusion
x
Pediatric xGI xfunction x- xpH xincreases xgradually- xreaches xadult xlevels x@ x20-30
xmonths x
x
preemies xare xeven
xslower
x
Diarrhea xand xkids x- xkids xwith xdiarrhea xhave xpoor xabsorption xof xoral xdrugs x
x
Pediatric xskin xabsorption x- xKids xhave xthinner xstratum xcorneum xso xtopical xmedications
xare x
x
absorbed xmore xreadily: xincreased xrisk xof
xtoxicity
x
Infants xand xLipid xSoluble xdrugs x- xdecreased xvolume xdistribution, xless xplasma xproteins
xfor x
